540788 ASPIRA

Aspira Pathlab & Diagnostics Share Price

₹60.30 -0.9 (-1.47%)

26 Dec, 2024 18:04

SIP TrendupStart SIP in ASPIRA

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -11.19%
  • Over 3 Month + 38.21%
  • Over 6 Month + 122.92%
  • Over 1 Year + 53.91%
SIP Lightning

Smart Investing Starts Here Start SIP with Aspira Pathlab & Diagnostics for Steady Growth!

Invest Now

Aspira Pathlab & Diagnostics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Aspira Pathlab & Diagnostics Financials

Aspira Pathlab & Diagnostics Technicals

EMA & SMA

Current Price
₹60.30
-0.9 (-1.47%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 11
  • 20 Day
  • ₹65.50
  • 50 Day
  • ₹60.86
  • 100 Day
  • ₹52.77
  • 200 Day
  • ₹45.19

Resistance and Support

61.2 Pivot Speed
  • R3 61.20
  • R2 61.20
  • R1 61.20
  • S1 61.20
  • S2 61.20
  • S3 61.20

What's your outlook on Aspira Pathlab & Diagnostics?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aspira Pathlab & Diag has an operating revenue of Rs. 14.63 Cr. on a trailing 12-month basis. An annual revenue de-growth of -8% needs improvement, Pre-tax margin of -20% needs improvement, ROE of -51% is poor and needs improvement. The company has a reasonable debt to equity of 21%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 53% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 87 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 42 indicates it belongs to a fair industry group of Medical-Services and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aspira Pathlab & Diagnostics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results
2024-05-28 Audited Results
2024-02-13 Quarterly Results
2024-02-10 Quarterly Results

Aspira Pathlab & Diagnostics F&O

Aspira Pathlab & Diagnostics Shareholding Pattern

18.55%
61.27%
20.18%

About Aspira Pathlab & Diagnostics

  • NSE Symbol
  • ASPIRA
  • BSE Symbol
  • 540788
  • Managing Director & CEO
  • Dr. Pankaj J Shah
  • ISIN
  • INE500C01017

Similar Stocks to Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics FAQs

Aspira Pathlab & Diagnostics share price is ₹60 As on 26 December, 2024 | 17:50

The Market Cap of Aspira Pathlab & Diagnostics is ₹62.1 Cr As on 26 December, 2024 | 17:50

The P/E ratio of Aspira Pathlab & Diagnostics is -229.1 As on 26 December, 2024 | 17:50

The PB ratio of Aspira Pathlab & Diagnostics is 11.9 As on 26 December, 2024 | 17:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23